Organon Canada Inc. / Organon Canada inc.
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Introduction, amendment, passage or defeat of any Bill or resolution in or before the Legislative Assembly, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
To actively promote the value of the pharmaceutical industry for British Columbia's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in British Columbia. As part of the initiatives, Organon Canada Inc. seeks to have its products listed on the relevant BC PharmaCare program formulary and enhance publicly funded women’s health initiatives/programs.
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Introduction, amendment, passage or defeat of any Bill or resolution in or before the Legislative Assembly, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
To contribute to British Columbia’s economic prosperity by recommending policies that will attract increased investment. Activities could include providing recommendations on tax policies, research programs and policies, as well as policies and programs regarding innovation. Focus of lobbying efforts is on representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in British Columbia, including under the BC PharmaCare programs. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the BC PharmaCare programs.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Introduction, amendment, passage or defeat of any Bill or resolution in or before the Legislative Assembly
|
Health
|